Publication:
Investigation of the Therapeutic Efficacy of Codelivery of psiRNA-Vascular Endothelial Growth Factor and pIL-4 into Chitosan Nanoparticles in the Breast Tumor Model

Simple item page
dc.contributor.authorEREN, FATİH
dc.contributor.authorsSalva, Emine; Turan, Suna O.; Kabasakal, Levent; Alan, Saadet; Ozkan, Naziye; Eren, Fatih; Akbuga, Julide
dc.date.accessioned2022-03-13T12:46:34Z
dc.date.available2022-03-13T12:46:34Z
dc.date.issued2014
dc.description.abstractAngiogenesis has been known to increase tumor growth and for its metastatic potential in human tumors. Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis and is a promising therapeutic target for breast cancer. VEGF is an essential target for RNAi-based gene therapy of breast cancer. Interleukin-4 (IL-4) may act as an anti-angiogenic molecule that inhibits tumor growth and migration in rats. The purpose of the present study was to improve therapeutic efficacy in breast cancer with the codelivery of siRNA-expressing plasmid targeting VEGF and IL-4-expressing plasmid encapsulating into chitosan nanoparticles (NPs). The codelivery of psiVEGF and pIL-4 plasmids greatly enhanced in vitro and in vivo gene-silencing efficiency. For the in vitro study, when psiVEGF and pIL-4 into chitosan NPs were combined (81%), the gene-silencing effect was higher than psiVEGF and pIL-4 NPs alone. The in vivo study breast tumor model demonstrated that the administration of coencapsulation of psiVEGF and pIL-4 into chitosan NPs caused an additive effect on breast tumor growth inhibition (97%), compared with containing NPs psiVEGF or pIL-4 alone. These results indicate that chitosan NPs can be effectively used for the codelivery of pIL-4 and siVEGF-expressing plasmid in a combination therapy against breast cancer. (c) 2013 Wiley Periodicals, Inc.
dc.identifier.doi10.1002/jps.23815
dc.identifier.eissn1520-6017
dc.identifier.issn0022-3549
dc.identifier.pubmed24357345
dc.identifier.urihttps://hdl.handle.net/11424/237942
dc.identifier.wosWOS:000331392900002
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofJOURNAL OF PHARMACEUTICAL SCIENCES
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectRNA interference
dc.subjectVEGF
dc.subjectIL-4
dc.subjectchitosan nanoparticles
dc.subjectbreast cancer
dc.subjectSIRNA DELIVERY
dc.subjectRNA INTERFERENCE
dc.subjectPLASMID DNA
dc.subjectINTERLEUKIN-4
dc.subjectANGIOGENESIS
dc.subjectEXPRESSION
dc.subjectPOLYMORPHISM
dc.subjectINHIBITION
dc.subjectCOMPLEXES
dc.subjectCARRIER
dc.titleInvestigation of the Therapeutic Efficacy of Codelivery of psiRNA-Vascular Endothelial Growth Factor and pIL-4 into Chitosan Nanoparticles in the Breast Tumor Model
dc.typearticle
dspace.entity.typePublication
local.avesis.idf9056023-3d2e-4132-90b5-06fb29e2261d
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages11
oaire.citation.endPage795
oaire.citation.issue3
oaire.citation.startPage785
oaire.citation.titleJOURNAL OF PHARMACEUTICAL SCIENCES
oaire.citation.volume103
relation.isAuthorOfPublication4bc77d63-5aa7-4c67-8d60-12778ea963b1
relation.isAuthorOfPublication.latestForDiscovery4bc77d63-5aa7-4c67-8d60-12778ea963b1

Files

Collections

Research Outputs